Tiziana Life Sciences (TLSA) Cash & Equivalents (2017 - 2025)

Tiziana Life Sciences' Cash & Equivalents history runs 9 years deep, the most recent figure standing at $4.0 million for Q4 2025.

• In Q4 2025, Cash & Equivalents rose 7.68% year-over-year to $4.0 million; the TTM figure through Dec 2025 stood at $4.0 million (up 7.68% YoY), while the FY2025 annual figure was $4.0 million, up 7.68% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $4.0 million, down from $7.3 million in the prior quarter.
• The five-year high for Cash & Equivalents was $53.3 million in Q2 2021, with the low at $1.1 million in Q2 2024.
• The 5-year median for Cash & Equivalents is $6.9 million (2023), against an average of $16.4 million.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents sank 93.47% in 2023, then jumped 541.68% in 2025.
• Tiziana Life Sciences' Cash & Equivalents stood at $42.2 million in 2021, then plunged by 57.04% to $18.1 million in 2022, then tumbled by 93.47% to $1.2 million in 2023, then soared by 214.79% to $3.7 million in 2024, then increased by 7.68% to $4.0 million in 2025.
• Business Quant data shows TLSA's Cash & Equivalents at $4.0 million in Q4 2025, $7.3 million in Q2 2025, and $3.7 million in Q4 2024.